Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
141 studies found for:    "Muscular Dystrophy, Duchenne"
Show Display Options
Rank Status Study
21 Completed Safety Study of Flavocoxid in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Flavocoxid
22 Recruiting Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: Epigallocatechin-Gallate;   Drug: Placebo
23 Active, not recruiting Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: eplerenone;   Drug: placebo
24 Completed Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: PTC124
25 Completed Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: AVI-4658 (PMO)
26 Recruiting Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention:
27 Recruiting L-citrulline and Metformin in Becker's Muscular Dystrophy
Condition: Becker's Muscular Dystrophy (BMD)
Interventions: Drug: Metformin and Metformin & L-Citrulline;   Drug: L-Citrulline and Metformin & L-Citrulline
28 Enrolling by invitation Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: PRO044 SC 6 mg/kg;   Drug: PRO044 IV 6 mg/kg;   Drug: PRO044 IV 9 mg/kg
29 Terminated Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Ataluren
30 Unknown  Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Biological: human umbilical cord mesenchymal stem cells
31 Unknown  The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
Conditions: Duchenne Muscular Dystrophy;   Cardiomyopathies
Intervention: Drug: Carvedilol
32 Recruiting Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Prednisolone
33 Recruiting Research of Biomarkers in Duchenne Muscular Dystrophy Patients
Condition: Duchenne Muscular Dystrophy (DMD)
Intervention:
34 Withdrawn Test-Retest Reliability of Pulmonary Function Tests in Patients With Duchenne's Muscular Dystrophy
Conditions: Duchenne's Muscular Dystrophy;   Scoliosis
Intervention:
35 Recruiting Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)
Condition: Becker Muscular Dystrophy
Intervention: Drug: (-)-epicatechin
36 Recruiting Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: PRO045, 0.15 mg/kg/week;   Drug: PRO045, 1.0 mg/kg/week;   Drug: PRO045, 3.0 mg/kg/week;   Drug: PRO045, 6.0 mg/kg/week;   Drug: PRO045, 9.0 mg/kg/week;   Drug: PRO045, selected dose
37 Recruiting Observational Study of Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 Skipping
Condition: Duchenne Muscular Dystrophy
Intervention:
38 Enrolling by invitation Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Conditions: Becker Muscular Dystrophy;   Sporadic Inclusion Body Myositis
Intervention: Biological: rAAV1.CMV.huFollistatin344
39 Recruiting Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy
Conditions: Muscular Dystrophy;   Duchenne Muscular Dystrophy
Intervention: Other: Intralesional/ Intravenous of Autologous Stem cells.
40 Recruiting A Phase I/II Study of PRO053 in Subjects With Duchenne Muscular Dystrophy (DMD)
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: Cohort 1;   Drug: Cohort 2;   Drug: 48-week treatment phase

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years